187 related articles for article (PubMed ID: 25956280)
1. Long-term results of fractionated stereotactic radiotherapy as third-line treatment in acromegaly.
Diallo AM; Colin P; Litre CF; Diallo MM; Decoudier B; Bertoin F; Higel B; Patey M; Rousseaux P; Delemer B
Endocrine; 2015 Dec; 50(3):741-8. PubMed ID: 25956280
[TBL] [Abstract][Full Text] [Related]
2. Acromegaly: a single centre's experience of stereotactic radiosurgery and radiotherapy for growth hormone secreting pituitary tumours with the linear accelerator.
Wilson PJ; De-Loyde KJ; Williams JR; Smee RI
J Clin Neurosci; 2013 Nov; 20(11):1506-13. PubMed ID: 23911106
[TBL] [Abstract][Full Text] [Related]
3. Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit.
Roug S; Rasmussen AK; Juhler M; Kosteljanetz M; Poulsgaard L; Heebøll H; Roed H; Feldt-Rasmussen U
Eur J Endocrinol; 2010 Apr; 162(4):685-94. PubMed ID: 20133445
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated Radiotherapy for Pituitary Somatotroph Adenomas.
Lian X; Shen J; Gu Z; Yan J; Sun S; Hou X; You H; Xing B; Zhu H; Shen J; Zhang F
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32930785
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of hypofractionated stereotactic radiotherapy with CyberKnife for growth hormone-secreting pituitary adenoma: evaluation by the Cortina consensus.
Iwata H; Sato K; Nomura R; Tabei Y; Suzuki I; Yokota N; Inoue M; Ohta S; Yamada S; Shibamoto Y
J Neurooncol; 2016 Jun; 128(2):267-75. PubMed ID: 26961771
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic conformal radiotherapy in patients with growth hormone-secreting pituitary adenoma.
Milker-Zabel S; Zabel A; Huber P; Schlegel W; Wannenmacher M; Debus J
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1088-96. PubMed ID: 15234043
[TBL] [Abstract][Full Text] [Related]
7. Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas.
Paek SH; Downes MB; Bednarz G; Keane WM; Werner-Wasik M; Curran WJ; Andrews DW
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):795-808. PubMed ID: 15708259
[TBL] [Abstract][Full Text] [Related]
8. Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: a 5.25-year follow-up study.
Schalin-Jäntti C; Valanne L; Tenhunen M; Setälä K; Paetau A; Sane T; Kouri M
Clin Endocrinol (Oxf); 2010 Jul; 73(1):72-7. PubMed ID: 20039898
[TBL] [Abstract][Full Text] [Related]
9. Long-term Outcome After Fractionated Radiotherapy for Pituitary Adenoma: The Curse of the Secretory Tumor.
Scheick S; Amdur RJ; Kirwan JM; Morris CG; Mendenhall WM; Roper S; Friedman W
Am J Clin Oncol; 2016 Feb; 39(1):49-54. PubMed ID: 25007040
[TBL] [Abstract][Full Text] [Related]
10. The role of stereotactic radiosurgery in the multimodal management of growth hormone-secreting pituitary adenomas.
Stapleton CJ; Liu CY; Weiss MH
Neurosurg Focus; 2010 Oct; 29(4):E11. PubMed ID: 20887121
[TBL] [Abstract][Full Text] [Related]
11. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas.
Minniti G; Traish D; Ashley S; Gonsalves A; Brada M
Clin Endocrinol (Oxf); 2006 May; 64(5):542-8. PubMed ID: 16649974
[TBL] [Abstract][Full Text] [Related]
12. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
Shimon I; Jallad RS; Fleseriu M; Yedinak CG; Greenman Y; Bronstein MD
Eur J Endocrinol; 2015 Jun; 172(6):707-13. PubMed ID: 25792375
[TBL] [Abstract][Full Text] [Related]
13. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
Maiza JC; Vezzosi D; Matta M; Donadille F; Loubes-Lacroix F; Cournot M; Bennet A; Caron P
Clin Endocrinol (Oxf); 2007 Aug; 67(2):282-9. PubMed ID: 17524029
[TBL] [Abstract][Full Text] [Related]
14. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
15. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
[TBL] [Abstract][Full Text] [Related]
16. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
Minniti G; Jaffrain-Rea ML; Osti M; Esposito V; Santoro A; Solda F; Gargiulo P; Tamburrano G; Enrici RM
Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
[TBL] [Abstract][Full Text] [Related]
17. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission.
Pollock BE; Jacob JT; Brown PD; Nippoldt TB
J Neurosurg; 2007 May; 106(5):833-8. PubMed ID: 17542527
[TBL] [Abstract][Full Text] [Related]
18. Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry.
Knappe UJ; Petroff D; Quinkler M; Schmid SM; Schöfl C; Schopohl J; Stieg MR; Tönjes A;
Eur J Endocrinol; 2020 Mar; 182(3):275-284. PubMed ID: 31917680
[TBL] [Abstract][Full Text] [Related]
19. Radiation treatment strategies for acromegaly.
Rowland NC; Aghi MK
Neurosurg Focus; 2010 Oct; 29(4):E12. PubMed ID: 20887122
[TBL] [Abstract][Full Text] [Related]
20. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.
Abbassioun K; Amirjamshidi M; Mehrazin A; Khalatbary I; Keynama M; Bokai H; Abdollahi M
Surg Neurol; 2006 Jul; 66(1):26-31; discussion 31. PubMed ID: 16793431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
